MediWound Ltd. is a global leader in developing enzymatic therapeutics for non-surgical tissue repair. Their approved product, NexoBrid®, is used for early burn eschar removal, while their pipeline includes EscharEx® for chronic wounds and MW005 for basal cell carcinoma. These innovative therapies aim to improve patient outcomes, reduce healthcare costs, and minimize the need for surgery.
mediwound.com
Ofer Gonen
Chief Executive Officer
Lior Rosenberg
Founder